Tecentriq 1 200 mg concentrate for solution for infusion
UC-0160/1717
Phase 3 small_molecule active
Quick answer
Tecentriq 1 200 mg concentrate for solution for infusion for High-risk non-muscle invasive bladder cancer (NMIBC) after transurethral resection of the bladder (TURBT) and pathological assessment. is a Phase 3 program (small_molecule) at Cancer Prevention Pharma (Ireland) Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Cancer Prevention Pharma (Ireland) Limited
- Indication
- High-risk non-muscle invasive bladder cancer (NMIBC) after transurethral resection of the bladder (TURBT) and pathological assessment.
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active